Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF ROXADUSTAT FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

Intervention/treatment:
ROXADUSTAT (AZD9941)
Medical condition:
CHRONIC KIDNEY DISEASE (CKD)
Protocol code:
D5740C00001
Control number:
179277
Status:
Closed
Approved:
November 28, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02174627
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 130 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Clinical Lead
Organization
AstraZeneca
Phone:
+1 302 885 1180
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Edmonton, Alberta, T6G 2B7

British Columbia

Research Site
Kamloops, British Columbia, V2C 2T1
Research Site
New Westminster, British Columbia, V3L 0A6

Manitoba

Research Site
Winnipeg, Manitoba, R2V 3M3

New Brunswick

Research Site
Saint John, New Brunswick, E2L 4L2

Nova Scotia

Research Site
Sydney, Nova Scotia, B1P 1P3

Ontario

Research Site
Brampton, Ontario, L6R 3J7
Research Site
Brampton, Ontario, L6T 0G1
Research Site
Kitchener, Ontario, N2H 5Z8
Research Site
London, Ontario, N6A 5A5
Research Site
Oakville, Ontario, L6K 3V3
Research Site
Scarborough Village, Ontario, M1H 3G4
Research Site
Toronto, Ontario, M4C 5T2
Research Site
Toronto, Ontario, M4S 1Y2
Research Site
Toronto, Ontario, M5C 2T2
Research Site
Toronto, Ontario, M9N 1N8
Research Site
Whitby, Ontario, L1N 5T2

Quebec

Research Site
Gatineau, Quebec, J8Y 6S8
Research Site
Greenfield Park, Quebec, J4V 2H1
Research Site
Montreal, Quebec, H1T 2M4
Research Site
Montreal, Quebec, H4J 1C5
Research Site
Quebec, Quebec, G1R 2J6

Results

See the results from the trial NCT02174627. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?